A Stage-Based Approach to Therapy in Parkinson’s Disease

Parkinson’s disease (PD) is a neurodegenerative disorder that features progressive, disabling motor symptoms, such as bradykinesia, rigidity, and resting tremor. Nevertheless, some non-motor symptoms, including depression, REM sleep behavior disorder, and olfactive impairment, are even earlier features of PD. At later stages, apathy, impulse control disorder, neuropsychiatric disturbances, and cognitive impairment can present, and they often become a heavy burden for both patients and caregivers. Indeed, PD increasingly compromises activities of daily life, even though a high variability in clinical presentation can be observed among people affected. Nowadays, symptomatic drugs and non-pharmaceutical treatments represent the best therapeutic options to improve quality of life in PD patients. The aim of the present review is to provide a practical, stage-based guide to pharmacological management of both motor and non-motor symptoms of PD. Furthermore, warning about drug side effects, contraindications, as well as dosage and methods of administration, are highlighted here, to help the physician in yielding the best therapeutic strategies for each symptom and condition in patients with PD.

[1]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  J. Jankovic,et al.  Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. , 2019, Parkinsonism & related disorders.

[3]  R. Hauser,et al.  Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. , 2019, Parkinsonism & related disorders.

[4]  E. Poliakoff,et al.  Parkinson’s-adapted cognitive stimulation therapy: feasibility and acceptability in Lewy body spectrum disorders , 2019, Journal of Neurology.

[5]  A. Lang,et al.  Dystonia and Parkinson's disease: What is the relationship? , 2019, Neurobiology of Disease.

[6]  M. Okun,et al.  Emerging therapies in Parkinson disease — repurposed drugs and new approaches , 2019, Nature Reviews Neurology.

[7]  J. Massano,et al.  Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review , 2019, Drugs.

[8]  W. Poewe,et al.  Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions , 2019, European journal of neurology.

[9]  K. Rejdak,et al.  Continuous subcutaneous apomorphine monotherapy in Parkinson's disease. , 2019, Annals of agricultural and environmental medicine : AAEM.

[10]  A. Tafreshi,et al.  Extended-Release Amantadine for Levodopa-Induced Dyskinesia , 2019, Expert review of neurotherapeutics.

[11]  H. Park,et al.  1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells , 2019, Molecules.

[12]  R. Pahwa,et al.  Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial , 2019, The Lancet Neurology.

[13]  Daniel Weintraub,et al.  Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.

[14]  Sarah Diamond,et al.  Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! , 2019, Expert review of neurotherapeutics.

[15]  R. Laureno,et al.  Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia , 2019, Journal of movement disorders.

[16]  A. Sack,et al.  Cognitive Stimulation for Individuals with Parkinson's Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study , 2018, Parkinson's disease.

[17]  V. Kostic,et al.  Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients , 2018, Expert opinion on pharmacotherapy.

[18]  R. Hauser,et al.  Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease , 2018, Movement disorders clinical practice.

[19]  J. C. Martínez‐Castrillo Impulse control disorders in Parkinson’s disease: a hard-turning point , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[20]  D. Pachito,et al.  Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review , 2018, Journal of the Neurological Sciences.

[21]  C. Sampaio,et al.  International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[22]  J. Assmus,et al.  Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease , 2018, Acta neurologica Scandinavica.

[23]  S. Federico,et al.  A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge? , 2018, Mini reviews in medicinal chemistry.

[24]  D. Truong,et al.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors , 2018, Journal of Neural Transmission.

[25]  Jorik Nonnekes,et al.  Freezing of gait: Promising avenues for future treatment. , 2018, Parkinsonism & related disorders.

[26]  E. Deeks Mirabegron: A Review in Overactive Bladder Syndrome , 2018, Drugs.

[27]  S. Pallesen,et al.  Impulse-Control Disorders in Parkinson’s Disease: A Meta-Analysis and Review of Case–Control Studies , 2018, Front. Neurol..

[28]  Alberto J Espay,et al.  Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.

[29]  ▼ Safinamide for Parkinson’s disease , 2018, Drug and Therapeutics Bulletin.

[30]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[31]  L. Timmermann,et al.  Management of constipation in patients with Parkinson’s disease , 2018, npj Parkinson's Disease.

[32]  Jose-Alberto Palma,et al.  Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies , 2018, Movement disorders : official journal of the Movement Disorder Society.

[33]  Jeffrey M. Hausdorff,et al.  Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[34]  A. Lang,et al.  Caffeine as symptomatic treatment for Parkinson disease (Café-PD) , 2017, Neurology.

[35]  C. Carroll,et al.  Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress , 2017, Journal of Parkinson's disease.

[36]  Xia Shen,et al.  Long-term effects of exercise and physical therapy in people with Parkinson disease , 2017, Nature Reviews Neurology.

[37]  N. Greig,et al.  Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.

[38]  A. West,et al.  LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model , 2017, Molecular therapy. Nucleic acids.

[39]  C. Tanner,et al.  ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial , 2017, JAMA neurology.

[40]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[41]  D. Claassen,et al.  Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease , 2017, Clinical Autonomic Research.

[42]  John-Paul Taylor,et al.  Psychosis in parkinsonism: an unorthodox approach , 2017, Neuropsychiatric disease and treatment.

[43]  Giuseppe Di Giovanni,et al.  Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry , 2017, Progress in Neurobiology.

[44]  G. Plazzi,et al.  Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. , 2017, Sleep medicine.

[45]  S. Fox,et al.  Motor Complications of Dopaminergic Medications in Parkinson's Disease , 2017, Seminars in Neurology.

[46]  H. Fernandez,et al.  Dopamine agonist withdrawal syndrome: A comprehensive review , 2017, Journal of the Neurological Sciences.

[47]  A. Cox,et al.  Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin , 2017, Neuropsychiatric disease and treatment.

[48]  J. Ferreira,et al.  Opicapone for the treatment of Parkinson’s disease , 2017, Expert opinion on pharmacotherapy.

[49]  W. Poewe,et al.  Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial , 2017, JAMA neurology.

[50]  D. James Surmeier,et al.  Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.

[51]  C. Chapple,et al.  Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia , 2017, Expert review of clinical pharmacology.

[52]  M. Grundman,et al.  First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.

[53]  S. Fox,et al.  Novel Levodopa Formulations for Parkinson’s Disease , 2016, CNS Drugs.

[54]  H. Fernandez,et al.  Current Understanding of Psychosis in Parkinson’s Disease , 2016, Current Psychiatry Reports.

[55]  J. Daneault,et al.  The Effects of Physical Activity in Parkinson’s Disease: A Review , 2016, Journal of Parkinson's disease.

[56]  P. Odin,et al.  Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances. , 2016, Current opinion in neurology.

[57]  J. Morgan,et al.  Treating the Motor Symptoms of Parkinson Disease , 2016, Continuum.

[58]  Bernhard Elsner,et al.  Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease. , 2016, The Cochrane database of systematic reviews.

[59]  S. Sveinbjornsdottir The clinical symptoms of Parkinson's disease , 2016, Journal of neurochemistry.

[60]  W. Poewe,et al.  Mavoglurant in Parkinson's patients with l‐Dopa‐induced dyskinesias: Two randomized phase 2 studies , 2016, Movement disorders : official journal of the Movement Disorder Society.

[61]  Alan J. Thomas,et al.  Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations , 2016, Acta neuropathologica communications.

[62]  S. Fox,et al.  Nondopaminergic treatments for Parkinson's disease: current and future prospects. , 2016, Neurodegenerative disease management.

[63]  T. Foltynie,et al.  The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. , 2016, Drug discovery today.

[64]  R. Hauser,et al.  Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial , 2016, Movement disorders : official journal of the Movement Disorder Society.

[65]  J. Jankovic,et al.  Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia , 2016, Drugs.

[66]  L. Bubacco,et al.  Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View , 2016, Current neuropharmacology.

[67]  Y Ben-Shlomo,et al.  Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[68]  J. Borovac Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology , 2016, The Yale journal of biology and medicine.

[69]  T. van Laar,et al.  Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. , 2016, Parkinsonism & related disorders.

[70]  T. Warnecke,et al.  Dysphagia in Parkinson’s Disease , 2016, Dysphagia.

[71]  V. Fung,et al.  Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients , 2016, Movement disorders : official journal of the Movement Disorder Society.

[72]  S. Lorenzl,et al.  A consensus review on the development of palliative care for patients with chronic and progressive neurological disease , 2016, European journal of neurology.

[73]  M. Stacy,et al.  Disease-Modifying Drugs in Parkinson’s Disease , 2015, Drugs.

[74]  P. Martínez-Martín,et al.  Double-blind Randomized Trial of t-DCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training , 2015, Brain Stimulation.

[75]  Alice Nieuwboer,et al.  Transcranial direct current stimulation in Parkinson's disease: Neurophysiological mechanisms and behavioral effects , 2015, Neuroscience & Biobehavioral Reviews.

[76]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[77]  Günther Deuschl,et al.  MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[78]  Klaus Seppi,et al.  Probable RBD and association with neurodegenerative disease markers: A population‐based study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[79]  Y. Kim,et al.  Efficacy of cumulative high-frequency rTMS on freezing of gait in Parkinson’s disease , 2015, Restorative neurology and neuroscience.

[80]  O. Tysnes,et al.  Development of excessive daytime sleepiness in early Parkinson disease , 2015, Neurology.

[81]  M. Onofrj,et al.  Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism , 2015, Medicine.

[82]  Cynthia Fox,et al.  Evidence-based treatment of voice and speech disorders in Parkinson disease , 2015, Current opinion in otolaryngology & head and neck surgery.

[83]  D. Weintraub,et al.  Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[84]  S. Kusunoki,et al.  Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease , 2015, Dysphagia.

[85]  A. Rana,et al.  Parkinson’s disease: a review of non-motor symptoms , 2015, Expert review of neurotherapeutics.

[86]  L. Schneider,et al.  Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. , 2015, JAMA psychiatry.

[87]  M. Onofrj,et al.  Dopamine Transporter Single-Photon Emission Computerized Tomography Supports Diagnosis of Akinetic Crisis of Parkinsonism and of Neuroleptic Malignant Syndrome , 2015, Medicine.

[88]  E. Tolosa,et al.  Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD , 2015, Neurology.

[89]  Tanya Simuni,et al.  Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. , 2015, JAMA.

[90]  A. Björklund,et al.  Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study , 2015, Brain : a journal of neurology.

[91]  M. Tagliati,et al.  Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. , 2015, Parkinsonism & related disorders.

[92]  A. Lang,et al.  Behavioral effects of levodopa , 2015, Movement disorders : official journal of the Movement Disorder Society.

[93]  P. Dasgupta,et al.  Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3‐adrenoceptor agonist (Mirabegron) for overactive bladder (OAB) , 2015, BJU international.

[94]  Susan H Fox,et al.  Clinical spectrum of levodopa‐induced complications , 2015, Movement disorders : official journal of the Movement Disorder Society.

[95]  M. Ziman,et al.  A Systematic Review and Meta-Analysis of Strength Training in Individuals With Multiple Sclerosis Or Parkinson Disease , 2015, Medicine.

[96]  P. Lewitt,et al.  Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.

[97]  R. Freeman,et al.  Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa , 2014, Hypertension.

[98]  A. Hohler,et al.  Management of orthostatic hypotension in patients with Parkinson's disease , 2014, Practical Neurology.

[99]  D. Jennings,et al.  Imaging prodromal Parkinson disease , 2014, Neurology.

[100]  C. Counsell,et al.  Mortality in Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[101]  J. Crippa,et al.  Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series , 2014, Journal of clinical pharmacy and therapeutics.

[102]  M. Tagliati,et al.  Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[103]  Matthew Rizzo,et al.  Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting , 2014, Neurology.

[104]  Filippo Brighina,et al.  Transcranial direct current stimulation for treatment of freezing of gait: A cross‐over study , 2014, Movement disorders : official journal of the Movement Disorder Society.

[105]  T. Dawson,et al.  The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease , 2014, Scientific Reports.

[106]  Stephanie D. Wilson,et al.  A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. , 2014, JAMA neurology.

[107]  A. Lang,et al.  Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.

[108]  T. Foltynie,et al.  Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.

[109]  J. Cummings,et al.  Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial , 2014, The Lancet.

[110]  K. Kieburtz,et al.  Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.

[111]  L. Marsh,et al.  Anxiety in Parkinson’s disease: identification and management , 2014, Therapeutic advances in neurological disorders.

[112]  P. Stanzione,et al.  Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[113]  L. Defebvre,et al.  Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[114]  Tejas Sankar,et al.  Deep brain stimulation for Parkinson's disease and other movement disorders. , 2013, Current opinion in neurology.

[115]  E. Hirsch,et al.  Gait Disorders in Parkinsonian Monkeys with Pedunculopontine Nucleus Lesions: A Tale of Two Systems , 2013, The Journal of Neuroscience.

[116]  C. Plewnia,et al.  Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial , 2013, Brain : a journal of neurology.

[117]  J. Assmus,et al.  Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease , 2013, Acta neurologica Scandinavica.

[118]  Y. Mizuno,et al.  Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[119]  B. Boeve,et al.  Treatment outcomes in REM sleep behavior disorder. , 2013, Sleep medicine.

[120]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[121]  John D Sorkin,et al.  Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. , 2013, JAMA neurology.

[122]  M. Matsuura,et al.  Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. , 2013, Parkinsonism & related disorders.

[123]  A. Berardelli,et al.  Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease , 2013, European journal of neurology.

[124]  T. Paparrigopoulos,et al.  Agomelatine may improve REM sleep behavior disorder symptoms. , 2012, Journal of clinical psychopharmacology.

[125]  A. Strafella,et al.  Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[126]  Richard L. Doty,et al.  Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.

[127]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[128]  W. Oertel,et al.  Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[129]  M. Gundeti,et al.  Urinary tract dysfunction in Parkinson’s disease: a review , 2012, International Urology and Nephrology.

[130]  I. Maidment,et al.  Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. , 2012, The Cochrane database of systematic reviews.

[131]  G. P. Herbison,et al.  Which anticholinergic drug for overactive bladder symptoms in adults. , 2012, The Cochrane database of systematic reviews.

[132]  B. Abler,et al.  Neural reward processing under dopamine agonists: Imaging , 2011, Journal of the Neurological Sciences.

[133]  R. Sakakibara,et al.  Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study. , 2011, Parkinsonism & related disorders.

[134]  M. Mark,et al.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. , 2011, The American journal of psychiatry.

[135]  W. Poewe,et al.  The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[136]  C. Adler,et al.  MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.

[137]  G. Yener,et al.  The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[138]  P. Kempster,et al.  A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[139]  W. Ondo,et al.  Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. , 2011, Parkinsonism & related disorders.

[140]  G. Fink,et al.  Akinetic‐rigid and tremor‐dominant Parkinson's disease patients show different patterns of FP‐CIT Single photon emission computed tomography , 2011, Movement disorders : official journal of the Movement Disorder Society.

[141]  S. Konitsiotis,et al.  Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[142]  A. Albanese,et al.  EFNS guidelines on diagnosis and treatment of primary dystonias , 2011, European journal of neurology.

[143]  K. Hisanaga,et al.  Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial , 2010, PloS one.

[144]  D. Kunz,et al.  A two‐part, double‐blind, placebo‐controlled trial of exogenous melatonin in REM sleep behaviour disorder , 2010, Journal of sleep research.

[145]  P. Calabresi,et al.  Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.

[146]  F. Horak,et al.  Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease , 2010, Neurology.

[147]  Roy W Jones,et al.  Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.

[148]  E. Londos,et al.  The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia , 2010, International journal of geriatric psychiatry.

[149]  T. Welty,et al.  Management of hallucinations and psychosis in Parkinson's disease. , 2010, The American journal of geriatric pharmacotherapy.

[150]  Grant D. Huang,et al.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.

[151]  P. Barone,et al.  Neurotransmission in Parkinson’s disease: beyond dopamine , 2010, European journal of neurology.

[152]  J. Friedman,et al.  Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis , 2010, Neuropsychopharmacology.

[153]  S. Auerbach,et al.  Best practice guide for the treatment of REM sleep behavior disorder (RBD). , 2010, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[154]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[155]  A. Schapira,et al.  Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis , 2009, European journal of neurology.

[156]  B. Bloem,et al.  Multidisciplinary care for patients with Parkinson's disease. , 2009, Parkinsonism & related disorders.

[157]  A. Antonini,et al.  Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.

[158]  D. Maraganore,et al.  Medical records documentation of constipation preceding Parkinson disease , 2009, Neurology.

[159]  R. Hauser,et al.  Review: Improving symptom control in early Parkinson’s disease , 2009, Therapeutic advances in neurological disorders.

[160]  J. Shneerson Successful Treatment of REM Sleep Behavior Disorder With Sodium Oxybate , 2009, Clinical neuropharmacology.

[161]  M. Dafotakis,et al.  Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis , 2009, Journal of Clinical Neuroscience.

[162]  E. Tolosa,et al.  Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. , 2008, Sleep.

[163]  R. Postuma,et al.  Manifestations of Parkinson disease differ in association with REM sleep behavior disorder , 2008, Movement disorders : official journal of the Movement Disorder Society.

[164]  Pablo Mir,et al.  Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.

[165]  C. Davie A review of Parkinson's disease. , 2008, British medical bulletin.

[166]  J. Ferreira,et al.  Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.

[167]  J. Jankovic Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[168]  R. Sakakibara,et al.  Bladder and bowel dysfunction in Parkinson’s disease , 2008, Journal of Neural Transmission.

[169]  T. Anderson,et al.  A Pilot Study of Respiration and Swallowing Integration in Parkinson’s Disease: “On” and “Off” Levodopa , 2008, Dysphagia.

[170]  M W Mahowald,et al.  Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. , 2007, Brain : a journal of neurology.

[171]  W. Poewe Depression in Parkinson's disease , 2007, Journal of Neurology.

[172]  K. Gwinn‐Hardy,et al.  Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group , 2007, Movement disorders : official journal of the Movement Disorder Society.

[173]  H. Braak,et al.  Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons , 2007, Acta Neuropathologica.

[174]  A. Antonini,et al.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.

[175]  D. Aarsland,et al.  Insomnia in Parkinson’s disease: frequency and progression over time , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[176]  K. Fuxe,et al.  Targeting adenosine A2A receptors in Parkinson's disease , 2006, Trends in Neurosciences.

[177]  J. Jankovic,et al.  Treatment of dystonia , 2006, The Lancet Neurology.

[178]  J. Langston,et al.  Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.

[179]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[180]  José Luis Molinuevo,et al.  Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study , 2006, The Lancet Neurology.

[181]  C. Fowler,et al.  Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management , 2006, Movement disorders : official journal of the Movement Disorder Society.

[182]  A. Lieberman Depression in Parkinson's disease – a review , 2006, Acta neurologica Scandinavica.

[183]  M. Onofrj,et al.  Akinetic crisis, acute akinesia, neuroleptic malignant‐like syndrome, Parkinsonism–hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal , 2005, Movement disorders : official journal of the Movement Disorder Society.

[184]  Jack J. Chen,et al.  A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. , 2005, Clinical therapeutics.

[185]  Esra Kılıç,et al.  Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder , 2005, Clinical Neurology and Neurosurgery.

[186]  Dag Aarsland,et al.  Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.

[187]  M. Onofrj,et al.  Acute akinesia in Parkinson disease , 2005, Neurology.

[188]  W Poewe,et al.  Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.

[189]  N. Borges Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy , 2005, Expert opinion on drug safety.

[190]  R. Miall,et al.  Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey , 2004, Neuroreport.

[191]  M. Onofrj,et al.  Improvement of motor function in early Parkinson disease by safinamide , 2004, Neurology.

[192]  Richard Gray,et al.  Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients , 2004, BMJ : British Medical Journal.

[193]  E. Wolters,et al.  Cognitive dysfunction and dementia in Parkinson’s disease , 2004, Journal of Neural Transmission.

[194]  R. Dewey,et al.  Management of motor complications in Parkinson’s disease , 2004, Neurology.

[195]  S. Factor,et al.  Rapid treatment of “off” episodes , 2004, Neurology.

[196]  J. Obeso,et al.  The origin of motor fluctuations in Parkinson’s disease , 2004, Neurology.

[197]  J. Montplaisir,et al.  The effects of pramipexole in REM sleep behavior disorder , 2003, Neurology.

[198]  Alan J. Thomas,et al.  What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia , 2003, International journal of geriatric psychiatry.

[199]  K. Jellinger The association of incident dementia with mortality in PD , 2003, Neurology.

[200]  B. Boeve,et al.  Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. , 2003, Sleep medicine.

[201]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[202]  C. Clarke,et al.  Amantadine in Parkinson's disease. , 2003, Lancet.

[203]  K. Marder,et al.  The association of incident dementia with mortality in PD , 2002, Neurology.

[204]  R. Brown,et al.  Apathy in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[205]  G. Halliday,et al.  Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. , 2002, Brain : a journal of neurology.

[206]  D. Garcia-Borreguero,et al.  Decreased phasic EMG activity during rapid eye movement sleep in treatment‐naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness , 2002, Movement disorders : official journal of the Movement Disorder Society.

[207]  S. Gilbody,et al.  Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials , 2002, Schizophrenia Research.

[208]  N. Uchimura,et al.  Melatonin therapy for REM sleep behavior disorder , 2001 .

[209]  L. Metman,et al.  Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study , 2001, Movement disorders : official journal of the Movement Disorder Society.

[210]  K. Walsh,et al.  Parkinson's disease and anxiety , 2001, Postgraduate medical journal.

[211]  M. Schiess,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. , 2000, Neurology.

[212]  C. Warren Olanow,et al.  Tolcapone and Hepatotoxic Effects , 2000 .

[213]  B. Boeve,et al.  Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. , 2000, Brain : a journal of neurology.

[214]  R. Llinás,et al.  Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[215]  E. Tolosa,et al.  Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.

[216]  S Fahn,et al.  Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.

[217]  R. Roth,et al.  Comparison of Neurotoxicity following Repeated Administration of L-Dopa, D-Dopa, and Dopamine to Embryonic Mesencephalic Dopamine Neurons in Cultures Derived from Fisher 344 and Sprague-Dawley Donors , 1997 .

[218]  S. Daniel,et al.  Olfactory dysfunction in Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[219]  A. Brzezinski Melatonin in humans. , 1997, The New England journal of medicine.

[220]  R Kieburtz,et al.  Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.

[221]  M. Mahowald,et al.  Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. , 1996, The American journal of medicine.

[222]  J. Hubble,et al.  Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.

[223]  E. Melamed,et al.  Psychosis in advanced Parkinson's disease , 1995, Neurology.

[224]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[225]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[226]  M. Mahowald,et al.  REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature , 1993 .

[227]  R. Palluk,et al.  Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans , 1992, Clinical pharmacology and therapeutics.

[228]  R. Doty,et al.  Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[229]  J. Kornhuber,et al.  Pharmacotoxic psychosis after memantine in Parkinson's disease , 1991, The Lancet.

[230]  E. Perry,et al.  Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.

[231]  J. Nutt,et al.  Peripheral pharmacokinetics of apomorphine in humans , 1989, Annals of neurology.

[232]  R. McCarley,et al.  Cholinergic activation of medial pontine reticular formation neurons in vitro , 1989, Brain Research.

[233]  M Onofrj,et al.  Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. , 1988, Electroencephalography and clinical neurophysiology.

[234]  E. Tolosa,et al.  Parkinson's disease with depression , 1986, Neurology.

[235]  A. Morrison,et al.  Different behaviors during paradoxical sleep without atonia depend on pontine lesion site , 1982, Brain Research.

[236]  H. Pakkenberg,et al.  PARKINSON'S DISEASE TREATED WITH SINEMET OR MADOPAR , 1976 .

[237]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[238]  A. Carlsson,et al.  3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.

[239]  J. Friedman,et al.  Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia. , 2017, The Journal of neuropsychiatry and clinical neurosciences.

[240]  J. Kulisevsky,et al.  Apathy in Parkinson's Disease. , 2017, International review of neurobiology.

[241]  K. Nakashima,et al.  Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial. , 2016, Internal medicine.

[242]  Á. Sesar,et al.  Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study. , 2016, Journal of Parkinson's disease.

[243]  M. Zigmond,et al.  Exercise: is it a neuroprotective and if so, how does it work? , 2014, Parkinsonism & related disorders.

[244]  Suneil K. Kalia,et al.  Parkinson hastalığı ve diğer hareket bozuklukları için derin beyin stimülasyonu , 2013 .

[245]  K. Chaudhuri,et al.  Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.

[246]  M. Nirenberg,et al.  Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.

[247]  R. Zweig,et al.  Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. , 2010, Parkinsonism & related disorders.

[248]  R. Trosch,et al.  Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s Disease , 2008, CNS drugs.

[249]  S. Papapetropoulos A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease , 2008 .

[250]  M. Onofrj,et al.  Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.

[251]  Y. Ben-Shlomo,et al.  Speech and language therapy for dysarthria in Parkinson's disease. , 2001, The Cochrane database of systematic reviews.

[252]  P. Foley The L-DOPA story revisited. Further surprises to be expected? , 2000, Journal of neural transmission. Supplementum.

[253]  D. Rye Contributions of the pedunculopontine region to normal and altered REM sleep. , 1997, Sleep.

[254]  W. Danielczyk Twenty-five years of amantadine therapy in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.

[255]  G. Pezzoli,et al.  Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[256]  Mahowald,et al.  Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. , 1993, Journal of sleep research.

[257]  A. Hughes,et al.  Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.

[258]  R. Kurlan,et al.  Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.

[259]  E. Quigley,et al.  Gastrointestinal symptoms in Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.

[260]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[261]  M. Ghilardi,et al.  Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. , 1988, Life sciences.

[262]  H. Pakkenberg,et al.  Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. , 1976, Acta Neurologica Scandinavica.